II Editor
18 Jan 2016
NEW ARTICLE: Viewpoint: Why AstraZeneca is undervalued "The rejection of LSE
FZfizer's proposed offer for LSE:AZN:AstraZeneca has seen shares in the latter fall back to a level at which we believe its substantial pipeline potential is undervalued. We took the precaution of reducing our holding in ..."[link]
II Editor
18 Jan 2016
NEW ARTICLE: Viewpoint: Deal or no deal for AstraZeneca "LSEFZfizer's recent bid approach for LSE:AZN:AstraZeneca has presented investors with a classic dilemma. Would shareholders choose the allure of a substantial short-term profit and, for those who elected not to sell immediately, a new equity ..."[link]
